Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).
Deep learning for early osteoporosis risk prediction
Osteoporosis is so difficult to detect in early stage it’s called the “silent disease.” What if artificial intelligence could help predict a patient’s chances of
June 28, 2024